71777-390 : Vitrakvi 25 mg Oral Capsule
| NDC: | 71777-390 |
| Labeler: | Loxo Oncology, Inc. |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Vitrakvi |
| Dosage Form: | Oral Capsule |
| Application #: | NDA210861 |
| Rev. Date: |
Appearance:
| Markings: | LOXO;LARO;25mg |
| Shapes: |
Capsule |
| Colors: |
 White |
| Size (mm): | 18 |
| Segments: * | 1 |
* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines. | |
NDC Package Codes:
- 71777-390-01: 60 CAPSULE IN 1 BOTTLE (71777‑390‑01)
Active Ingredients:
- Larotrectinib
Dosage Strength:
- 25 mg
Inactive Ingredients:
- Gelatin, Unspecified
- Titanium Dioxide /
Pharmaceutical Classes:
- Kinase Inhibitor [EPC]
- Tropomyosin Receptor Kinases Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 71777-391 Vitrakvi 100 mg Oral Capsule by Loxo Oncology, Inc.
- 71777-392 Vitrakvi 20 mg/ml Oral Solution by Loxo Oncology, Inc.
- 50419-390 Vitrakvi 25 mg Oral Capsule by Bayer Healthcare Pharmaceuticals Inc.
- 50419-391 Vitrakvi 100 mg Oral Capsule by Bayer Healthcare Pharmaceuticals Inc.
- 50419-392 Vitrakvi 20 mg/ml Oropharyngeal Solution, Concentrate by Bayer Healthcare Pharmaceuticals Inc.
- 50419-393 Vitrakvi 20 mg/ml Oropharyngeal Solution, Concentrate by Bayer Healthcare Pharmaceuticals Inc.
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 71776-100Next: 71777-391 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.